Merck's melanoma win sent the stock surging and raised confidence that its drug pipeline can keep growing beyond its blockbuster cancer drug. The same day, Moderna jumped 11% and BioNTech rose too, showing investors are once again willing to pay up for bi

Verdict: a well-built watch-list, not a trade — wait for the cooldown

The idea that Merck's melanoma win marks a biotech-wide mood shift has a genuinely strong anchor: Merck's FY2025 free cash flow of $12.4B ranks in the 99.6th percentile of Health Care peers and its 34.7% return on equity sits in the 86th, while BioNTech turned free-cash-flow positive ($280.9M, 94th percentile) against a $7.7B cash pile. Against that, two of the three legs are fundamentally weak — Moderna's revenue fell 39.9% with a -158% operating margin and 0th-percentile free cash flow, and BioNTech's revenue remains 85% below its 2021 peak — and the trade itself is unconfirmed: over 1,237 daily bars (60 months) the entry rules never triggered, BioNTech's RSI of 80.1 has already breached the strategy's own 75 overbought ceiling, and no robust parameter setup was established in sensitivity testing. The 2.4% stop is also very tight for names like Moderna (101.3% annualized volatility, 72.6% historical max drawdown), risking shakeouts on noise. **Conviction breakdown:** Thesis support 60 — Merck's fundamentals carry it, but the sector-mood claim leans on Moderna's dire financials. Trade readiness 45 — a watch-list setup by design, but zero historical triggers and no validated parameter variant. Risk quality 45 — tight stops and a modelled 69.6% expected max drawdown for the basket. Trigger proximity 40 — trend conditions are met, but the momentum confirmation needs a cooldown that may never come. Fundamentals trend 60 — Merck strong, BioNTech stabilising, Moderna deteriorating.

Trade now

**Today, this is a watch-list setup, not a buy.** The entry needs four things to line up on a daily bar: price above the 20-day average, a fresh MACD line crossing above its signal line, RSI (14) above 50, and RSI still below 75. The trend conditions are comfortably met — MRK sits near $156.5, roughly $17 (about 11%) above its 20-day average at $139.5 — but the momentum-confirmation piece is the problem: MACD crossed above its signal days ago, not now, and every one of these names is pressing the overbought ceiling that the strategy treats as a wall. The RSI conditions tell the story. MRK's RSI (14) is 74.5 and Moderna's is 73.6 — both just barely inside the "below 75" entry gate — while BioNTech's RSI is 80.1, already through it. That means BNTX's entry conditions cannot be met right now at all, and MRK and MRNA need either a small cooldown toward the mid-60s on RSI plus a fresh MACD cross, or nothing fires. Chasing here would contradict the strategy's own discipline, and the 60-month rule evaluation over roughly 1,240 daily bars for MRK opened zero positions — the entry has simply never lined up in this configuration, which is exactly why you wait rather than improvise a looser version. If a fresh signal does trigger, the risk framework is tight by design: a hard stop at a 2.4% loss, a take-profit at 4.8% (an effective 2:1 reward-to-risk), a trend-break exit on any daily close below the 20-day average, an overbought exit if RSI pushes above 75, and a 60-bar time stop. Position sizing is fixed-risk, risking about 2.4% of equity per trade with a 25% maximum position. On MRK at an illustrative entry near $156.5, the stop sits near $152.7 and the profit target near $163.9. "Wait" means concretely: no position today; set alerts on the MACD signal-line cross for all three names and re-check RSI daily. A pullback of a few days that holds the 20-day average and resets RSI into the 55–70 zone is the setup you want. Note also that no robust nearby-parameter setup was established in sensitivity testing, so the published thresholds stand as-is.

Why the momentum thesis has real fuel behind it

The core of this idea is that Merck's melanoma win marks a sector-wide mood shift, and the fundamentals give that argument more support than a typical headline rally. Merck is the anchor: FY2025 revenue of $65.0B grew modestly (1.3% year over year), but the quality metrics are what carry the thesis — a 34.7% return on equity (86th percentile among Health Care peers), $12.4B in free cash flow (99.6th percentile of 757 peers), and a 74.8% gross margin. This is not a stretched story stock; it is a cash machine whose pipeline news, per the Yahoo Finance piece on the melanoma win, extends the growth runway beyond its blockbuster cancer drug. BioNTech adds a second, self-funding leg. Despite a net loss of $1.1B in FY2025, BioNTech carries $7.7B in cash…

Scores

• Conviction score breakdown: 50
• Thesis support: 60
• Trade readiness: 45
• Risk quality: 45
• Trigger proximity: 40
• Fundamentals trend: 60

Watch items

• MRK — RSI (14)
• MRK — Price vs 20-day average
• MRK — MACD (12,26,9) signal-line cross
• BNTX — RSI (14)
• MRNA — RSI (14)
• MRNA — Price vs 20-day average
• BNTX — Price above EMA (20)
• BNTX — MACD (12,26,9) crossed above MACD (12,26,9)
• BNTX — RSI (14) above 50
• BNTX — RSI (14) below 75